Peptide Report
FOXO4-DRI Peptide Report
Catalog report for FOXO4-DRI, generated from Peptide Stacks product data and linked to the matching PeptideReports protocol page when available.
Common Uses
People commonly discuss FOXO4-DRI in healthy-aging and cellular-senescence conversations, usually as part of broader longevity and resilience routines.
How It Works
FOXO4-DRI is discussed as a peptide designed to interfere with the FOXO4-p53 interaction in senescent cells. That disruption is studied for allowing damaged senescent cells to enter apoptosis rather than remaining metabolically active.
Storage
Powder form: In lyophilized powder form, FOXO4-DRI is generally kept sealed, dry, protected from direct light, and refrigerated unless the product label or certificate of analysis gives different handling instructions. Avoid leaving vials in hot rooms, vehicles, direct sunlight, or other temperature swings, because moisture, heat, and light are the main storage conditions people try to control before reconstitution.
Reconstituted: After reconstitution, FOXO4-DRI should generally be treated as more sensitive: keep it refrigerated, minimize unnecessary handling, avoid shaking, and use clean handling practices each time the vial is accessed. Follow the product label, protocol page, and any pharmacy or lab guidance for beyond-use timing; if the solution changes color, becomes cloudy, develops particles, or the vial integrity is questionable, it should not be used.
Protocol
The full FOXO4-DRI protocol is included below. The standalone protocol page remains available if you want to open it separately.
Open Standalone Protocol
Scope
Preparation examples, syringe conversion, community-reported patterns and important limitations.
Available strengths: 10 MG
Preparation Examples
These are calculation examples only. The concentration assumptions below are explicit so syringe units are never separated from vial strength and diluent volume.
| Setup |
Diluent |
Concentration |
Unit conversion |
| 10 MG vial – 2 mL example |
Add 2 mL bacteriostatic water |
5 mg/mL |
Each U-100 unit = 50 mcg |
| 10 MG vial – 1 mL example |
Add 1 mL bacteriostatic water |
10 mg/mL |
Each U-100 unit = 100 mcg |
Syringe Conversion
| Reported amount |
10 MG setup |
10 MG setup |
| 1 mg |
20 units |
10 units |
| 2.5 mg |
50 units |
25 units |
| 5 mg |
100 units |
50 units |
| 10 mg |
200 units |
100 units |
Always recalculate from the actual vial strength and diluent volume. A U-100 unit is 0.01 mL; it is not a dose by itself.
Community-Reported Patterns
| Recurring report |
Frequency seen |
Context in reports |
| 2-5 mg |
Intermittent |
Lower experimental reports |
| 5-10 mg |
Every other day in short cycles |
Senolytic discussions |
| Variable mg/kg |
Short research cycles |
Highly inconsistent reports |
Observations
- Community discussions most often centered on senescent-cell and longevity research.
- The amount, frequency, route and cycle length varied substantially between reports.
- Reported outcomes were commonly confounded by diet, training, other products or existing treatment.
Caveats
- FOXO4-DRI is highly experimental with no established human safety or dosing standard; senolytic effects could cause unpredictable tissue injury.
- Community reports are uncontrolled anecdotes and do not establish an appropriate dose, safety, product identity, purity or efficacy.